Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo

Executive Summary

Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.

You may also be interested in...



Roche Inks RNA-Targeted Small Molecule Pact With Ribometrix

Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.

Vertex Inks RNA Splicing Pact With Skyhawk

In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.

Bristol Licenses Dragonfly’s IL-12 Program To Boost Immunotherapies

The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC125551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel